
BeiGene Ltd (ONC) Stock Forecast & Price Target
BeiGene Ltd (ONC) Analyst Ratings
Bulls say
BeOne Medicines is expected to continue on a positive trajectory due to strong sales of their main product Brukinsa, expansion into new therapeutic areas, and potential for accelerated approval for their other drugs. The company's promising pipeline and positive reception from experts bode well for future revenue growth. Despite a setback in their CELESTIAL-301 trial, analysts remain bullish on BeOne's overall potential in the biotech industry and foresee potential stock price growth in the next year.
Bears say
BeOne Medicines is a commercial-stage biotech firm that produces oncology therapeutics, with their main product, Brukinsa, making up 74% of total revenue. They have two other approved commercialized drugs in their portfolio, but those generate the majority of their revenue from China. The company is also advancing more than 50 drugs in clinical trials. However, there are risks to the investment thesis, including clinical development, competition, regulatory and sector risks. Additionally, their flagship product is on track to generate over $5B in worldwide revenues in 2026, and their Phase 3 trials for various programs have demonstrated positive results. However, there may be concerns about the potential for competitive drugs and the length of the clinical trial process. It will be important to closely monitor the success and progression of their current pipeline and the company's ability to maintain competitive advantages in the market.
This aggregate rating is based on analysts' research of BeiGene Ltd and is not a guaranteed prediction by Public.com or investment advice.
BeiGene Ltd (ONC) Analyst Forecast & Price Prediction
Start investing in BeiGene Ltd (ONC)
Order type
Buy in
Order amount
Est. shares
0 shares